259 related articles for article (PubMed ID: 21940710)
61. Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification.
Beresini MH; Liu Y; Dawes TD; Clark KR; Orren L; Schmidt S; Turincio R; Jones SW; Rodriguez RA; Thana P; Hascall D; Gross DP; Skelton NJ
J Biomol Screen; 2014 Jun; 19(5):758-70. PubMed ID: 24518067
[TBL] [Abstract][Full Text] [Related]
62. Visual characterization and diversity quantification of chemical libraries: 2. Analysis and selection of size-independent, subspace-specific diversity indices.
Colliandre L; Le Guilloux V; Bourg S; Morin-Allory L
J Chem Inf Model; 2012 Feb; 52(2):327-42. PubMed ID: 22181665
[TBL] [Abstract][Full Text] [Related]
63. Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening.
Honarnejad S; van Boeckel S; van den Hurk H; van Helden S
SLAS Discov; 2021 Feb; 26(2):192-204. PubMed ID: 32734803
[TBL] [Abstract][Full Text] [Related]
64. Screening Library Design.
Ashenden SK
Methods Enzymol; 2018; 610():73-96. PubMed ID: 30390806
[TBL] [Abstract][Full Text] [Related]
65. A rapid and affordable screening platform for membrane protein trafficking.
Snyder JC; Pack TF; Rochelle LK; Chakraborty SK; Zhang M; Eaton AW; Bai Y; Ernst LA; Barak LS; Waggoner AS; Caron MG
BMC Biol; 2015 Dec; 13():107. PubMed ID: 26678094
[TBL] [Abstract][Full Text] [Related]
66. Extending kinome coverage by analysis of kinase inhibitor broad profiling data.
Jacoby E; Tresadern G; Bembenek S; Wroblowski B; Buyck C; Neefs JM; Rassokhin D; Poncelet A; Hunt J; van Vlijmen H
Drug Discov Today; 2015 Jun; 20(6):652-8. PubMed ID: 25596550
[TBL] [Abstract][Full Text] [Related]
67. Scopy: an integrated negative design python library for desirable HTS/VS database design.
Yang ZY; Yang ZJ; Lu AP; Hou TJ; Cao DS
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32892221
[TBL] [Abstract][Full Text] [Related]
68. Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays.
Gul S; Hadian K
Expert Opin Drug Discov; 2014 Dec; 9(12):1393-404. PubMed ID: 25374163
[TBL] [Abstract][Full Text] [Related]
69. High-Throughput Screening and Triage Assays Identify Small Molecules Targeting c-MYC in Cancer Cells.
Kallal LA; Waszkiewicz A; Jaworski JP; Della Pietra A; Berrodin T; Brady P; Jurewicz AJ; Zeng X; Payne L; Medina JR; Doepner-Buser C; Mangatt B
SLAS Discov; 2021 Feb; 26(2):216-229. PubMed ID: 33482073
[TBL] [Abstract][Full Text] [Related]
70. Luciferase Advisor: High-Accuracy Model To Flag False Positive Hits in Luciferase HTS Assays.
Ghosh D; Koch U; Hadian K; Sattler M; Tetko IV
J Chem Inf Model; 2018 May; 58(5):933-942. PubMed ID: 29667823
[TBL] [Abstract][Full Text] [Related]
71. Just-in-Time Compound Pooling Increases Primary Screening Capacity without Compromising Screening Quality.
Elkin LL; Harden DG; Saldanha S; Ferguson H; Cheney DL; Pieniazek SN; Maloney DP; Zewinski J; O'Connell J; Banks M
J Biomol Screen; 2015 Jun; 20(5):577-87. PubMed ID: 25722344
[TBL] [Abstract][Full Text] [Related]
72. Brief Guide: Experimental Strategies for High-Quality Hit Selection from Small-Molecule Screening Campaigns.
Rothenaigner I; Hadian K
SLAS Discov; 2021 Aug; 26(7):851-854. PubMed ID: 33882754
[TBL] [Abstract][Full Text] [Related]
73. Using Microscale Thermophoresis to Characterize Hits from High-Throughput Screening: A European Lead Factory Perspective.
Rainard JM; Pandarakalam GC; McElroy SP
SLAS Discov; 2018 Mar; 23(3):225-241. PubMed ID: 29460707
[TBL] [Abstract][Full Text] [Related]
74. Changing the HTS Paradigm: AI-Driven Iterative Screening for Hit Finding.
Dreiman GHS; Bictash M; Fish PV; Griffin L; Svensson F
SLAS Discov; 2021 Feb; 26(2):257-262. PubMed ID: 32808550
[TBL] [Abstract][Full Text] [Related]
75. Theoretical and experimental relationships between percent inhibition and IC50 data observed in high-throughput screening.
Gubler H; Schopfer U; Jacoby E
J Biomol Screen; 2013 Jan; 18(1):1-13. PubMed ID: 22853931
[TBL] [Abstract][Full Text] [Related]
76. Benefits of Strategic Small-Scale Targeted Screening.
Sharlow ER
Assay Drug Dev Technol; 2016 Aug; 14(6):329-32. PubMed ID: 27341343
[TBL] [Abstract][Full Text] [Related]
77. ChemFH: an integrated tool for screening frequent false positives in chemical biology and drug discovery.
Shi S; Fu L; Yi J; Yang Z; Zhang X; Deng Y; Wang W; Wu C; Zhao W; Hou T; Zeng X; Lyu A; Cao D
Nucleic Acids Res; 2024 Jul; 52(W1):W439-W449. PubMed ID: 38783035
[TBL] [Abstract][Full Text] [Related]
78. High-throughput fluorescence assay for small-molecule inhibitors of autophagins/Atg4.
Shu CW; Madiraju C; Zhai D; Welsh K; Diaz P; Sergienko E; Sano R; Reed JC
J Biomol Screen; 2011 Feb; 16(2):174-82. PubMed ID: 21245471
[TBL] [Abstract][Full Text] [Related]
79. Nuisance Compounds, PAINS Filters, and Dark Chemical Matter in the GSK HTS Collection.
Chakravorty SJ; Chan J; Greenwood MN; Popa-Burke I; Remlinger KS; Pickett SD; Green DVS; Fillmore MC; Dean TW; Luengo JI; Macarrón R
SLAS Discov; 2018 Jul; 23(6):532-545. PubMed ID: 29699447
[TBL] [Abstract][Full Text] [Related]
80. Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.
Paricharak S; Méndez-Lucio O; Chavan Ravindranath A; Bender A; IJzerman AP; van Westen GJP
Brief Bioinform; 2018 Mar; 19(2):277-285. PubMed ID: 27789427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
